Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
612.16B
Market cap612.16B
Price-Earnings ratio
28.31
Price-Earnings ratio28.31
Dividend yield
2.14%
Dividend yield2.14%
Average volume
10.44M
Average volume10.44M
High today
$255.08
High today$255.08
Low today
$246.11
Low today$246.11
Open price
$248.27
Open price$248.27
Volume
16.32M
Volume16.32M
52 Week high
$255.08
52 Week high$255.08
52 Week low
$151.01
52 Week low$151.01

Stock Snapshot

As of today, Johnson & Johnson(JNJ) shares are valued at $254.61. The company's market cap stands at 612.16B, with a P/E ratio of 28.31 and a dividend yield of 2.14%.

On 2026-06-27, Johnson & Johnson(JNJ) stock traded between a low of $246.11 and a high of $255.08. Shares are currently priced at $254.61, which is +3.5% above the low and -0.2% below the high.

Johnson & Johnson(JNJ) shares are trading with a volume of 16.32M, against a daily average of 10.44M.

During the past year, Johnson & Johnson(JNJ) stock moved between $151.01 at its lowest and $255.08 at its peak.

During the past year, Johnson & Johnson(JNJ) stock moved between $151.01 at its lowest and $255.08 at its peak.

JNJ News

Reuters 3h
Bruins acquire Mammoth F JJ Peterka for 2 first-rounders - Reuters

...

Bruins acquire Mammoth F JJ Peterka for 2 first-rounders - Reuters
Nasdaq 11h
Why Johnson & Johnson Stock Popped on Friday

Key Points Guggenheim analyst Vamil Divan raised his price target on Johnson & Johnson stock today. Upside is perhaps only 12% over the next year, however. 1...

Why Johnson & Johnson Stock Popped on Friday
TipRanks 11h
Johnson & Johnson presents new Imaavy data at EAN 2026 Congress

Johnson & Johnson announced new data across 12 abstracts at the European Academy of Neurology 2026 Congress that offer additional insight into the use of IMAAVY...

Analyst ratings

69%

of 26 ratings
Buy
69.2%
Hold
26.9%
Sell
3.8%

More JNJ News

Nasdaq 12h
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Key Points Bristol Myers Squibb maintains a robust biopharmaceutical portfolio focused on high-stakes oncology and immunology treatments. Johnson & Johnson le...

Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
24/7 Wall St. 14h
Dividend Safety Check: VIG and the Dividend Appreciation Approach

Dividend Safety Check: VIG and the Dividend Appreciation Approach By John Seetoo Published Jun 26, 10:00AM EDT Vanguard Dividend Appreciation ETF (VIG) — larg...

Dividend Safety Check: VIG and the Dividend Appreciation Approach
24/7 Wall St. 14h
The Portfolio That Quietly Pays Your Property Taxes Forever

The Portfolio That Quietly Pays Your Property Taxes Forever By Drew Wood Published Jun 26, 9:43AM EDT Quick Read Covering a $6,000 annual property tax bill re...

The Portfolio That Quietly Pays Your Property Taxes Forever
TipRanks 15h
Johnson & Johnson price target raised to $270 from $266 at Guggenheim

Guggenheim analyst Vamil Divan raised the firm’s price target on Johnson & Johnson to $270 from $266 and keeps a Buy rating on the shares ahead of the company k...

Nasdaq 17h
J&J CEO Now Sees 'Line of Sight' to Double-Digit Growth for His $100 Billion Company. Here's Why Investors Should Pay Attention.

Key Points Johnson & Johnson is on pace to generate roughly $100 billion in revenue in 2026. The company believes it has a unique opportunity to invest in its...

J&J CEO Now Sees 'Line of Sight' to Double-Digit Growth for His $100 Billion Company. Here's Why Investors Should Pay Attention.
Simply Wall St 1d
Johnson & Johnson Walks Away From Obesity Drugs To Chase Cancer Leadership

Johnson & Johnson (NYSE:JNJ) is stepping back from the obesity drug market to concentrate its pharmaceutical efforts on cancer treatments. The company is targe...

Johnson & Johnson Walks Away From Obesity Drugs To Chase Cancer Leadership
24/7 Wall St. 1d
One Stock to Own For Ultimate Dividend Safety

One Stock to Own For Ultimate Dividend Safety By Vandita Jadeja Published Jun 25, 12:27PM EDT Quick Read JNJ just raised its quarterly dividend 3.1% to $1.34,...

One Stock to Own For Ultimate Dividend Safety

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.